What is Good for the Heart is Good for the Brain According to NIH Report; Nymox Has Global Patent Rights for Statin Drugs for the Treatment and Prevention of Alzheimer's Disease.

HASBROUCK HEIGHTS, N.J. -- Reducing heart health risk factors may help maintain mental function in old age according to a new report from an expert panel of the National Institutes of Health (NIH) published in the current issue of Alzheimer's & Dementia (February 2006; 2:12-32). The panel surveyed the scientific and medical literature for strategies to preserve or enhance cognitive and emotional function as people grow older and highlighted the importance of controlling cardiovascular risk factors for maintaining brain health. Statins, a class of widely prescribed cholesterol-lowering drugs, have been shown in many studies to reduce the risk of cardiovascular disease and have been independently linked by other studies to lower risk of Alzheimer's disease.

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) holds U.S. and global patent rights for the use of statin drugs for the prevention and treatment of Alzheimer's disease (AD), including for patients at risk for AD because of vascular-related risk factors or disease. Alzheimer's disease is the leading cause of dementia in the elderly, afflicting an estimated 4.5 million people in the U.S. alone.

The potential use of statins to treat or prevent Alzheimer's disease has been widely reported in the peer-reviewed medical literature, both in terms of clinical data, (such as Neurology (2005; 65:1388-1394); J. Neurol. Neurosurg. Psychiatry (2005; 76:1624-1629) Arch Neurol (2005; 62:1047-51); Neurology (2005; 64:1531-8); Arch Neurol (2005; 62:753-7); J Neurol Sci (2005; 229-230:147-50); Arch Gen Psychiatry (2005; 62:217-24)) and possible mechanisms through which statins may prevent or slow the progression of Alzheimer's disease (such as J Neurosci Res (2005; 82:10-19); J Biol Chem (2005; M505268200); PLoS Med (2005; 2:e18); J Neurosci (2005; 25:299-307)). Recent expert articles reviewing the clinical and scientific evidence in the field have also highlighted the potential of statin drugs for the treatment or prevention of AD: The American Journal of Medicine (2005; 118: 48S-53S); The Lancet Neurology (2005; 4:841-852); Current Opinions in Lipidology (2005;16: 619-623); The Lancet Neurology (2005; 4: 521-2).

More information about Nymox is available at www.nymox.com, email: [e-mail], or 800-936-9669.

This press release contains certain "forward-looking statements" as defined in the United States Private Securities Litigation Reform Act of 1995 that involve a number of risks and uncertainties. There can be no assurance that such statements will prove to be accurate and the actual results and future events could differ materially from management's

current expectations. The conduct of clinical trials and the development of drug products involve substantial risks and uncertainties and actual results may differ materially from expectations. Promising early results do not ensure that later stage or larger scale clinical trials will be successful or will proceed as expected. Such factors are detailed from time to time in Nymox's filings with the United States Securities and Exchange Commission and other regulatory authorities.